Literature DB >> 17081126

Mast cell-dependent activation of pro matrix metalloprotease 2: A role for serglycin proteoglycan-dependent mast cell proteases.

Anders Lundequist1, Magnus Abrink, Gunnar Pejler.   

Abstract

The formation of active matrix metalloprotease-2 (MMP-2) requires the proteolytic processing of proMMP-2, a process that can occur through the formation of a ternary complex between proMMP-2, the tissue inhibitor of metalloprotease-2 and membrane type 1-MMP. However, other activation mechanisms have been suggested, and in this study we investigated whether mast cells (MCs) may play a role in the activation of proMMP-2. Murine peritoneal cells, a mixture of macrophages, lymphocytes and MCs, were cultured ex vivo. Addition of proMMP-2 to resting peritoneal cell cultures resulted in only slow conversion of proMMP-2 into the active enzyme. However, when MC degranulation was provoked using a calcium ionophore, proMMP-2 processing was markedly enhanced. When the peritoneal cell populations were depleted in MCs, proMMP-2 processing was abrogated, but was reconstituted when purified MCs were added to the depleted cultures. ProMMP-2 processing was sensitive to serine protease inhibitors, but not to inhibitors of other classes of proteases. Furthermore, proMMP-2 processing was completely abrogated in cells lacking serglycin, a proteoglycan that has previously been shown to mediate storage of a variety of MC serine proteases. Taken together, these results suggest a novel mode of proMMP-2 activation mediated by serglycin-dependent MC serine proteases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17081126     DOI: 10.1515/BC.2006.189

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  7 in total

Review 1.  Potential targets for intervention in radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Curr Drug Targets       Date:  2010-11       Impact factor: 3.465

2.  Mast cell chymase degrades the alarmins heat shock protein 70, biglycan, HMGB1, and interleukin-33 (IL-33) and limits danger-induced inflammation.

Authors:  Ananya Roy; Goutham Ganesh; Helena Sippola; Sara Bolin; Osama Sawesi; Anders Dagälv; Susan M Schlenner; Thorsten Feyerabend; Hans-Reimer Rodewald; Lena Kjellén; Lars Hellman; Magnus Åbrink
Journal:  J Biol Chem       Date:  2013-11-20       Impact factor: 5.157

3.  Preclinical research into basic mechanisms of radiation-induced heart disease.

Authors:  M Boerma; M Hauer-Jensen
Journal:  Cardiol Res Pract       Date:  2010-10-04       Impact factor: 1.866

Review 4.  Serglycin in human cancers.

Authors:  Xin-Jian Li; Chao-Nan Qian
Journal:  Chin J Cancer       Date:  2011-09

5.  Mouse mast cell protease 4 suppresses scar formation after traumatic spinal cord injury.

Authors:  Tim Vangansewinkel; Stefanie Lemmens; Nathalie Geurts; Kirsten Quanten; Dearbhaile Dooley; Gunnar Pejler; Sven Hendrix
Journal:  Sci Rep       Date:  2019-03-06       Impact factor: 4.379

6.  Proteomics of apheresis platelet supernatants during routine storage: Gender-related differences.

Authors:  Monika Dzieciatkowska; Angelo D'Alessandro; Timothy A Burke; Marguerite R Kelher; Ernest E Moore; Anirban Banerjee; Christopher C Silliman; Bernadette F West; Kirk C Hansen
Journal:  J Proteomics       Date:  2014-09-06       Impact factor: 4.044

7.  Targeting Serglycin Prevents Metastasis in Murine Mammary Carcinoma.

Authors:  Ananya Roy; Julia Femel; Elisabeth J M Huijbers; Dorothe Spillmann; Erik Larsson; Maria Ringvall; Anna-Karin Olsson; Magnus Åbrink
Journal:  PLoS One       Date:  2016-05-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.